1
|
Lau S, Makarem M, Cabanero M, Tsao MS, Bradbury P, Shepherd F, Liu G, Leighl N, Sacher A. 1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Corke L, García Pardo de Santayana M, Meteleva K, Shepherd F, Bradbury P, Eng L, Kuang S, Cabanero M, Rogalla P, Liu G, Tsao MS, Pugh T, Wang B, Ohashi P, Leighl N, Sacher A. 1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
3
|
Petricca J, French C, Ajaj R, Zelifan A, Grant B, Zhan L, Zhang Y, Thakral A, Nicholls D, Hsu YH, Pal P, Cabanero M, Tsao M, Liu G. EP11.02-001 Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Lau S, Rabindranath M, Weiss J, Li J, Nirmalakumar S, Ruff H, Boerner S, Tong L, Tsao M, Pal P, Cabanero M, Hsu Y, Fung A, Sacher A, Shepherd F, Liu G, Bradbury P, Yasufuku K, Czarnecka-Kujawa K, Ko H, Leighl N, Schwock J. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Stewart E, Martins-Filho S, Cabanero M, Wang A, Huang J, Bao H, Wu X, Patel D, Chen Z, Law J, Bradbury P, Shepherd F, Leighl N, Tsao M, Pugh T, Bratman S, Liu G, Sacher A. P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Hotte S, Winquist E, Chi K, Ellard S, Sridhar S, Emmenegger U, Salim M, Iqbal N, Canil C, Kollmannsberger C, Hansen A, Lalani AKA, Gingerich J, Finch D, Cabanero M, Wyatt A, Tu D, Vera-Badillo F, Seymour L, Smoragiewicz M. CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.044] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Tsao M, Shi R, Radulovich N, Ng C, Notsuda H, Cabanero M, Martins-Filho S, Raghavan V, Li Q, Mer A, Liu N, Pham N, Haibe-Kains B, Liu G, Moghal N. OA08.01 Organoid Cultures as Novel Preclinical Models of Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Perdrizet K, Stockley T, Law J, Shabir M, Zhang T, Le L, Lau A, Tsao M, Kamel-Reid S, Pal P, Cabanero M, Schwock J, Ko H, Liu G, Bradbury P, Sacher A, Shepherd F, Leighl N. P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Moraes F, Weiss J, Moskovitz M, Sorotsky H, Pintilie M, Leighl N, Bradbury P, Liu G, Zadeh G, Doherty M, Kia A, So J, Cabanero M, Pugh T, Sugumar V, Torti D, Tsao M, Torchia J, Shultz D, Shepherd F, Lok B. MA25.11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Martins-Filho S, Cabanero M, Pham N, Stewart E, Ravi D, Patel D, Mcconnell J, Grindlay A, Allison F, Li M, Shepherd F, Tsao M, Yasufuku K, Liu G. MA27.01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Wu L, Chan M, Mckee T, Butt S, Cabanero M, Green B, Duong B, Yun Z, Kohno M, Murakami J, Zhao Y, Kelley S, De Perrot M. P2.06-38 Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Cabanero M, Kuo J, Liu N, Tsao M. MA24.05 Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR-Mutant Lung Adenocarcinomas. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Abstract
The advent of targeted therapy in non-small-cell lung cancer (nsclc) has made the routine molecular diagnosis of EGFR mutations crucial for optimal patient management. Obtaining tumour tissue for biomarker testing, especially in the setting of re-biopsy, can present many challenges. A potential alternative source of tumour dna is circulating cell-free tumour-derived dna (ctdna). Although ctdna is present in low quantities in plasma, the convenience of sample acquisition and the increasing reliability of detection methods make this approach a promising one. The various performance characteristics of both digital and nondigital platforms are still variable, and a standardized approach is needed that will make those platforms reliable clinical tools for the detection of EGFR sensitizing mutations and resistance mutations, including the T790M resistance mutation. Information derived from ctdna can be used to assess tumour burden, to identify genomic-based resistance mechanisms, and to track dynamic changes during therapy.
Collapse
Affiliation(s)
- M Cabanero
- Princess Margaret Cancer Centre, University Health Network, and.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON
| | - M S Tsao
- Princess Margaret Cancer Centre, University Health Network, and.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON
| |
Collapse
|
14
|
Notsuda H, Radulovich N, Ng C, Tamblyn L, Cabanero M, Li M, Pham N, Tsao M. P1.02-016 Establishment of Lung Adenocarcinoma Organoid Cultures. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Shi R, Radulovich N, Cabanero M, Pintille M, Raghavan V, Quevedo R, Tamblyn L, Ng C, Stambolic V, Pugh T, Moghal N, Tsao M. P3.03-008 Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. ACTA ACUST UNITED AC 2017; 24:111-119. [PMID: 28490925 DOI: 10.3747/co.24.3524] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Starting in the early 2000s, non-small-cell lung cancer (nsclc) subtypes have evolved from being histologically described to molecularly defined. Management of lung adenocarcinomas now generally requires multiple molecular tests at baseline to define the optimal treatment strategy. More recently, second biopsies performed at progression in patients treated with tyrosine kinase inhibitors (tkis) have further defined the continued use of molecularly targeted therapy. In the present article, we focus on one molecular subtype: EGFR-mutated nsclc. For that patient population, multiple lines of tki therapy are now available either clinically or in clinical trials. Each line of treatment is guided by the specific mutations (for example, L858R, T790M, C797S) identified in EGFR. We first describe the various mechanisms of acquired resistance to EGFR tki treatment. We then focus on strategies that clinicians and pathologists can both use during tissue acquisition and handling to optimize patient results. We also discuss future directions for the molecular characterization of lung cancers with driver mutations, including liquid biopsies. Finally, we provide an algorithm to guide treating physicians managing patients with EGFR-mutated nsclc. The same framework can also be applied to other molecularly defined nsclc subgroups as resistance patterns are elucidated and additional lines of treatment are developed.
Collapse
Affiliation(s)
- M Cabanero
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON
| | - R Sangha
- Cross Cancer Institute, Edmonton, AB
| | | | - M Sukhai
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON
| | - M Pakkal
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON
| | - S Kamel-Reid
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON
| | | | | | - R A Juergens
- Juravinski Cancer Centre, McMaster University, Hamilton, ON
| | - C Butts
- Cross Cancer Institute, Edmonton, AB
| | - M S Tsao
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON
| |
Collapse
|
17
|
Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13:197-207. [PMID: 17486107 PMCID: PMC2527618 DOI: 10.1038/sj.mp.4002012] [Citation(s) in RCA: 490] [Impact Index Per Article: 30.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2007] [Revised: 03/26/2007] [Accepted: 03/29/2007] [Indexed: 11/09/2022]
Abstract
The genetic basis of bipolar disorder has long been thought to be complex, with the potential involvement of multiple genes, but methods to analyze populations with respect to this complexity have only recently become available. We have carried out a genome-wide association study of bipolar disorder by genotyping over 550,000 single-nucleotide polymorphisms (SNPs) in two independent case-control samples of European origin. The initial association screen was performed using pooled DNA, and selected SNPs were confirmed by individual genotyping. While DNA pooling reduces power to detect genetic associations, there is a substantial cost saving and gain in efficiency. A total of 88 SNPs, representing 80 different genes, met the prior criteria for replication in both samples. Effect sizes were modest: no single SNP of large effect was detected. Of 37 SNPs selected for individual genotyping, the strongest association signal was detected at a marker within the first intron of diacylglycerol kinase eta (DGKH; P=1.5 x 10(-8), experiment-wide P<0.01, OR=1.59). This gene encodes DGKH, a key protein in the lithium-sensitive phosphatidyl inositol pathway. This first genome-wide association study of bipolar disorder shows that several genes, each of modest effect, reproducibly influence disease risk. Bipolar disorder may be a polygenic disease.
Collapse
Affiliation(s)
- A E Baum
- Unit on the Genetic Basis of Mood and Anxiety Disorders, Mood and Anxiety Disorders Program, US Department of Health and Human Services, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|